An 8-isoprostane metabolite
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

8-iso-13,14-dihydro-15-keto Prostaglandin F2α

Item No. 16380

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(8β)-9α,11α-dihydroxy-15-oxo-prost-5Z-en-1-oic acid
CAS Number
191919-02-5
Synonyms
  • 8-iso-13,14-dihydro-15-keto PGF2α
Molecular Formula
C20H34O5
Formula Weight
354.5
Purity
≥98%
Formulation (Request formulation change)
A 500 µg/ml solution in methyl acetate
Solubility(Learn about Variance in Solubility)
10 mM Na2CO3: >6.5 mg/mlDMF: >100 mg/mlDMSO: >100 mg/mlEthanol: >100 mg/mlPBS (pH 7.2): >10 mg/ml
SMILES
O[C@@H]1[C@@H](C/C=C\CCCC(O)=O)[C@@H](CCC(CCCCC)=O)[C@H](O)C1
InChi Code
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-19,22-23H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17+,18-,19+/m0/s1
InChi Key
VKTIONYPMSCHQI-JPRPWBOBSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    50 µg

    $72

    Add

    100 µg

    $108

    Add

    500 µg

    $501

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    8-iso-13,14-dihydro-15-keto Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) is a metabolite of the isoprostane, 8-isoprostane (8-iso PGF2α), in rabbits, monkeys and humans.1 8-iso PGF2α is a PG-like product of non-specific lipid peroxidation.2 In both humans and monkeys, exogenously infused 8-isoprostane is converted primarily to metabolites having 2 or 4 carbon atoms removed from the top side chain by β-oxidation.1 A similar pattern is observed when tritiated 8-isoprostane is infused into rabbits.3 Early in the infusion (within 10 minutes) 8-iso-13,14-dihydro-15-keto PGF2α was a significant component of the metabolite profile, which was comprised mostly of dinor 8-isoprostane metabolites. 8-iso-13,14-dihydro-15-keto PGF2α weakly inhibits the U-46619 or collagen-induced aggregation of human platelets, although a number of the E-series isoprostanes are much more potent in this assay.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Chiabrando, C., Valagussa, A., Rivalta, C., et al. Identification and measurement of endogenous β-oxidation metabolites of 8-epi-prostaglandin F2α. The Journal of Biological Chemisty 274(3), 1313-1319 (1999).

    2. Morrow, J.D., Hill, K.E., Burk, R.F., et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87(23), 9383-9387 (1990).

    3. Basu, S. Metabolism of 8-iso-prostaglandin F2α. FEBS Lett. 428(112), 32-36 (1998).

    4. Cranshaw, J.H., Evans, T.W., and Mitchell, J.A. Charcterization of the effects of isoprostanes on platelet aggregation in human whole blood. Br. J. Pharmacol. 132(8), 1699-1706 (2001).